RT Journal Article
SR Electronic
T1 High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.06.16.155580
DO 10.1101/2020.06.16.155580
A1 Tiancheng Liu
A1 Jessica Hsiung
A1 Su Zhao
A1 Jessica Kost
A1 Deepika Sreedhar
A1 Kjerstie Olson
A1 Douglas Keare
A1 John Roche
A1 Carl V. Hanson
A1 Cynthia Press
A1 John Boggs
A1 Jorge P. Rodriguez-Soto
A1 Jose G. Montoya
A1 Meijie Tang
A1 Hongjie Dai
YR 2020
UL http://biorxiv.org/content/early/2020/06/17/2020.06.16.155580.abstract
AB The outbreak and rapid spread of SARS-CoV-2 virus has led to a dire global pandemic with millions of people infected and ~ 400,000 deaths thus far. Highly accurate detection of antibodies for COVID-19 is an indispensable part of the effort to combat the pandemic1,2. Here we developed two-plex antibody detection against SARS-CoV-2 spike proteins3 (the S1 subunit and receptor binding domain RBD) in human serum and saliva on a near-infrared nano-plasmonic gold (pGOLD) platform4–8. By testing nearly 600 serum samples, pGOLD COVID-19 assay achieved ~ 99.78 % specificity for detecting both IgG and IgM with 100 % sensitivity in sera collected > 14 days post disease symptom onset, with zero cross-reactivity to other diseases. Two-plex correlation analysis revealed higher binding of serum IgM to RBD than to S1. IgG antibody avidity toward multiple antigens were measured, shedding light on antibody maturation in COVID-19 patients and affording a powerful tool for differentiating recent from remote infections and identifying re-infection by SARS-CoV-2. Just as important, due to high analytical sensitivity, the pGOLD COVID-19 assay detected minute amounts of antibodies in human saliva, offering the first non-invasive detection of SARS-CoV-2 antibodies.Competing Interest StatementH. D. worked on this project as a consultant for Nirmidas Biotech Inc. independent of Stanford projects.